Cargando…
Stability and inactivation of SARS coronavirus
The SARS-coronavirus (SARS-CoV) is a newly emerged, highly pathogenic agent that caused over 8,000 human infections with nearly 800 deaths between November 2002 and September 2003. While direct person-to-person transmission via respiratory droplets accounted for most cases, other modes have not been...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086689/ https://www.ncbi.nlm.nih.gov/pubmed/15118911 http://dx.doi.org/10.1007/s00430-004-0219-0 |
_version_ | 1783509175011115008 |
---|---|
author | Rabenau, H. F. Cinatl, J. Morgenstern, B. Bauer, G. Preiser, W. Doerr, H. W. |
author_facet | Rabenau, H. F. Cinatl, J. Morgenstern, B. Bauer, G. Preiser, W. Doerr, H. W. |
author_sort | Rabenau, H. F. |
collection | PubMed |
description | The SARS-coronavirus (SARS-CoV) is a newly emerged, highly pathogenic agent that caused over 8,000 human infections with nearly 800 deaths between November 2002 and September 2003. While direct person-to-person transmission via respiratory droplets accounted for most cases, other modes have not been ruled out. Faecal shedding is common and prolonged and has caused an outbreak in Hong Kong. We studied the stability of SARS-CoV under different conditions, both in suspension and dried on surfaces, in comparison with other human-pathogenic viruses, including human coronavirus HCoV-229E. In suspension, HCoV-229E gradually lost its infectivity completely while SARS-CoV retained its infectivity for up to 9 days; in the dried state, survival times were 24 h versus 6 days. Thermal inactivation at 56°C was highly effective in the absence of protein, reducing the virus titre to below detectability; however, the addition of 20% protein exerted a protective effect resulting in residual infectivity. If protein-containing solutions are to be inactivated, heat treatment at 60°C for at least 30 min must be used. Different fixation procedures, e.g. for the preparation of immunofluorescence slides, as well as chemical means of virus inactivation commonly used in hospital and laboratory settings were generally found to be effective. Our investigations confirm that it is possible to care for SARS patients and to conduct laboratory scientific studies on SARS-CoV safely. Nevertheless, the agent’s tenacity is considerably higher than that of HCoV-229E, and should SARS re-emerge, increased efforts need to be devoted to questions of environmental hygiene. |
format | Online Article Text |
id | pubmed-7086689 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-70866892020-03-23 Stability and inactivation of SARS coronavirus Rabenau, H. F. Cinatl, J. Morgenstern, B. Bauer, G. Preiser, W. Doerr, H. W. Med Microbiol Immunol Original Investigation The SARS-coronavirus (SARS-CoV) is a newly emerged, highly pathogenic agent that caused over 8,000 human infections with nearly 800 deaths between November 2002 and September 2003. While direct person-to-person transmission via respiratory droplets accounted for most cases, other modes have not been ruled out. Faecal shedding is common and prolonged and has caused an outbreak in Hong Kong. We studied the stability of SARS-CoV under different conditions, both in suspension and dried on surfaces, in comparison with other human-pathogenic viruses, including human coronavirus HCoV-229E. In suspension, HCoV-229E gradually lost its infectivity completely while SARS-CoV retained its infectivity for up to 9 days; in the dried state, survival times were 24 h versus 6 days. Thermal inactivation at 56°C was highly effective in the absence of protein, reducing the virus titre to below detectability; however, the addition of 20% protein exerted a protective effect resulting in residual infectivity. If protein-containing solutions are to be inactivated, heat treatment at 60°C for at least 30 min must be used. Different fixation procedures, e.g. for the preparation of immunofluorescence slides, as well as chemical means of virus inactivation commonly used in hospital and laboratory settings were generally found to be effective. Our investigations confirm that it is possible to care for SARS patients and to conduct laboratory scientific studies on SARS-CoV safely. Nevertheless, the agent’s tenacity is considerably higher than that of HCoV-229E, and should SARS re-emerge, increased efforts need to be devoted to questions of environmental hygiene. Springer-Verlag 2004-04-29 2005 /pmc/articles/PMC7086689/ /pubmed/15118911 http://dx.doi.org/10.1007/s00430-004-0219-0 Text en © Springer-Verlag 2004 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Investigation Rabenau, H. F. Cinatl, J. Morgenstern, B. Bauer, G. Preiser, W. Doerr, H. W. Stability and inactivation of SARS coronavirus |
title | Stability and inactivation of SARS coronavirus |
title_full | Stability and inactivation of SARS coronavirus |
title_fullStr | Stability and inactivation of SARS coronavirus |
title_full_unstemmed | Stability and inactivation of SARS coronavirus |
title_short | Stability and inactivation of SARS coronavirus |
title_sort | stability and inactivation of sars coronavirus |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086689/ https://www.ncbi.nlm.nih.gov/pubmed/15118911 http://dx.doi.org/10.1007/s00430-004-0219-0 |
work_keys_str_mv | AT rabenauhf stabilityandinactivationofsarscoronavirus AT cinatlj stabilityandinactivationofsarscoronavirus AT morgensternb stabilityandinactivationofsarscoronavirus AT bauerg stabilityandinactivationofsarscoronavirus AT preiserw stabilityandinactivationofsarscoronavirus AT doerrhw stabilityandinactivationofsarscoronavirus |